The Expression Profiles and Clinical Significance of Mixed Lineage Kinases in Glioma
Jin Huang1, Yuankun Liu1, Gaosong Wang1
1The Affiliated Wuxi People's Hospital of Nanjing Medical University, Wuxi People's Hospital, Wuxi Medical Center, Nanjing Medical University, Nanjing, China.
Abstract:
Mixed lineage kinases (MLKs), comprising seven members: MLK1-4, dual leucine zipper kinase (DLK), leucine zipper kinase (LZK), and sterile alpha motif and leucine zipper containing kinase (ZAK), belong to the mitogen-activated protein kinase kinase kinase (MAP3K) family. These kinases are implicated in the progression of numerous cancers by activating mitogen-activated protein kinase (MAPK) cascades or functioning as ser/thr and tyr kinases. However, their specific roles in glioma remain elusive. In the present study, we utilized bioinformatics approaches to investigate the expression patterns of MLKs in low-grade gliomas (LGG) and glioblastoma multiforme (GBM). Additionally, we analyzed their clinical significance and delved into the potential mechanisms underlying MLK activity as well as their association with tumor-immune infiltrating cells (TIICs) in glioma. Furthermore, we conducted in vitro studies to elucidate the functional roles of MLK1-2 in glioma. Our findings revealed that the expressions of MLK1-2 were conspicuously downregulated in GBM and positively correlated with patients' overall survival. Conversely, ZAK exhibited an opposing trend. Notably, our newly devised risk score model exhibited superior performance in predicting patient prognoses. Moreover, we analyzed the potential mechanisms of MLK activity and its interplay with tumor immune infiltration. Last, we validated the antitumor effect of MLK1-2 at the in vitro level. In summary, our study sheds new insights into the roles of MLKs in glioma, particularly MLK1-2, and their potential as therapeutic targets.
Insights
Mixed lineage kinases (MLKs) show altered expression in glioma, with MLK1-2 downregulation linked to better survival. These findings highlight MLKs as potential therapeutic targets for brain tumors.
Area of Science:
- Oncology
- Molecular Biology
- Bioinformatics
Background:
- Mixed lineage kinases (MLKs) are MAP3K family members involved in cancer progression.
- Their specific roles in glioma, a primary brain tumor, are not well understood.
- Understanding MLK expression and function is crucial for developing new glioma therapies.
Purpose of the Study:
- To investigate MLK expression patterns in low-grade gliomas (LGG) and glioblastoma multiforme (GBM).
- To analyze the clinical significance and potential mechanisms of MLK activity in glioma.
- To explore the association between MLKs and tumor-immune infiltrating cells (TIICs) and validate MLK1-2's antitumor effects in vitro.
Main Methods:
- Bioinformatic analysis of MLK expression in LGG and GBM datasets.
- Correlation analysis of MLK expression with clinical outcomes and TIICs.
- In vitro functional studies on MLK1-2 in glioma cell models.
Main Results:
- MLK1-2 expression was significantly downregulated in GBM and correlated positively with patient overall survival.
- ZAK expression showed an inverse correlation with survival.
- A novel risk score model demonstrated high predictive accuracy for patient prognosis.
Conclusions:
- MLK1-2 downregulation in GBM suggests a tumor-suppressive role, contrasting with ZAK's potential oncogenic function.
- MLKs, particularly MLK1-2, represent promising therapeutic targets for glioma treatment.
- Further research into MLK mechanisms and their interaction with the tumor microenvironment is warranted.
More Related Videos
09:40Characterization of Functionally Associated miRNAs in Glioblastoma and their Engineering into Artificial Clusters for Gene Therapy
Published on: October 4, 2019
06:32Evaluation of Biomarkers in Glioma by Immunohistochemistry on Paraffin-Embedded 3D Glioma Neurosphere Cultures
Published on: January 9, 2019
Related Concept Videos
Interactions Between Signaling Pathways
Convergence and divergence, and cross-talk between signaling pathways
Two distinct signaling pathways can converge on a single functional unit, which may either be a single protein or a complex of proteins. The response is either functionally distinct or synergistic between the two pathways but different from the response...
mTOR Signaling and Cancer Progression
The mTOR pathway or the...
